ArticleCell reports. Medicine2025
Age-(in)dependent altered molecular mechanisms in Parkinson's disease through extracellular vesicle proteome and lipidome.
Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Research progress of blood-brain barrier penetrating and brain diseases therapy by natural biopolymer - based nanomedicine delivery systems.Materials today. Bio · 2026Review
- Extracellular vesicles as minimally invasive biomarkers and therapeutic platforms in rare neurological diseases.Frontiers in aging · 2026Review
- Harnessing Natural Extracellular Vesicles to Combat Age-Related Diseases: From Aging Drivers to Therapeutic Opportunities.International journal of nanomedicine · 2026Review
- Serum lipidomic alterations associated with post-stroke cognitive impairment: an exploratory prospective study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) remains insidious and clinically elusive at early stages due to the lack of precise, non-invasive biomarkers. Given their ability to cross the blood-brain barrier, extracellular vesicles (EVs) offer a promising platform for biomarker discovery in neurodegeneration. Using an affinity-based EV isolation method, we profile EV proteomes and lipidomes from plasma across life stages, followed by targeted validation via parallel reaction monitoring (PRM). We identify both age-independent and age-dependent EV biomarkers predictive of prodromal PD and capable of distinguishing PD from multiple system atrophy (MSA). Functional analyses reveal protein-lipid interactions contributing to PD pathophysiology, including lipid-mediated modulation of APOE signaling. Machine learning models integrating putative EV proteins achieve robust classification across age groups. Our findings demonstrate the diagnostic potential of EV-derived molecules for early PD detection and mechanistic insights, advancing a clinically applicable, non-invasive strategy for risk stratification and disease intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.